Drug Trial Radar · NCT07540897
A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Aug 13, 2026
Primary completion
Jun 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Alkermes, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.
Conditions
- Narcolepsy Type 1
Interventions
ALKS 2680 Dose 1Drug
Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks
ALKS 2680 Dose 2Drug
Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks
PlaceboDrug
Participants will receive placebo tablets, daily, orally for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in mean sleep latency (MSL) on Maintenance of Wakefulness Test (MWT) from baseline to Week 12 by dose levelTime frame: Baseline to Week 12
Locations
53 sites in 13 countries. Site status is shown where the registry gives one.
Alkermes Investigational Site
Scottsdale, Arizona · Recruiting
Alkermes Investigational Site
Brandon, Florida · Recruiting
Alkermes Investigational Site
Miami, Florida · Recruiting
Alkermes Investigational Site
Winter Park, Florida · Recruiting
Alkermes Investigational Site
Atlanta, Georgia · Recruiting
Alkermes Investigational Site
Macon, Georgia · Recruiting
Alkermes Investigational Site
Kansas City, Kansas · Recruiting
Alkermes Investigational Site
Lansing, Michigan · Recruiting
Alkermes Investigational Site
Novi, Michigan · Recruiting
Alkermes Investigational Site
Rochester, Minnesota · Recruiting
Alkermes Investigational Site
St Louis, Missouri · Recruiting
Alkermes Investigational Site
Amherst, New York · Recruiting
Alkermes Investigational Site
Charlotte, North Carolina · Recruiting
Alkermes Investigational Site
Raleigh, North Carolina · Recruiting
Alkermes Investigational Site
Cincinnati, Ohio · Recruiting
Alkermes Investigational Site
Cleveland, Ohio · Recruiting
Alkermes Investigational Site
Charleston, South Carolina · Recruiting
Alkermes Investigational Site
Colombia, South Carolina · Recruiting
Alkermes Investigational Site
Dallas, Texas · Recruiting
Alkermes Investigational Site
El Paso, Texas · Recruiting
Alkermes Investigational Site
Frisco, Texas · Recruiting
Alkermes Investigational Site
McKinney, Texas · Recruiting
Alkermes Investigational Site
San Antonio, Texas · Recruiting
Alkermes Investigational Site
Sugar Land, Texas · Recruiting
Alkermes Investigational Site
Norfolk, Virginia · Recruiting
Alkermes Investigational Site
Spokane, Washington · Recruiting
Alkermes Investigational Site
Macquarie Park, New South Wales, Australia · Recruiting
Alkermes Investigational Site
Edegem, Belgium · Recruiting
Alkermes Investigational Site
Ghent, Belgium · Recruiting
Alkermes Investigational Site
Namur, Belgium · Recruiting
Alkermes Investigational Site
Markham, Ontario, Canada · Recruiting
Alkermes Investigational Site
Toronto, Ontario, Canada · Recruiting
Alkermes Investigational Site
Sherbrooke, Quebec, Canada · Recruiting
Alkermes Investigational Site
Helsinki, Finland · Recruiting
Alkermes Investigational Site
Schwerin, Mecklenburg-Vorpommern, Germany · Recruiting
Alkermes Investigational Site
Berlin, State of Berlin, Germany · Recruiting
Alkermes Investigational Site
Berlin, State of Berlin, Germany · Recruiting
Alkermes Investigational Site
Bologna, Italy · Recruiting
Alkermes Investigational Site
Verona, Italy · Recruiting
Alkermes Investigational Site
Kitakyushu, Fukuoka, Japan · Recruiting
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.